Source: ClinicalTrials.gov — U.S. National Library of Medicine — A database of privately and publicly funded clinical studies conducted around the world (U.S. National Library of Medicine, public domain).
This page lists clinical trials related to Pituitary Disorders from the ClinicalTrials.gov database.
Trial Summary
- Total studies: 50
- Recruiting: 22
- Active, not recruiting: 5
- Completed: 15
- Other: 8
Results are refreshed periodically and may not reflect the most current information available from ClinicalTrials.gov.
Recruiting Trials
NCT00001159 — Natural History of Thyroid Function Disorders
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Enrollment | 2500 |
| Study Type | OBSERVATIONAL |
| Conditions | Hyperthyroidism; Hypothyroidism; Grave’s Disease |
Participants in this study will be patients diagnosed with or suspected to have a thyroid function disorder. These conditions may include: hypothyroidism, hyperthyroidism, thyroid hormone resistance, Graves’ Dermopathy, and thyroid-stimulating hormone (TSH) secreting pituitary adenomas.
The main purpose of this study is to further understand the natural history, clinical presentation, and gene…
NCT00001595 — An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Enrollment | 2000 |
| Study Type | OBSERVATIONAL |
| Conditions | Panhypopituitarism; Gigantism/Acromegaly; Prolactinoma; Cushing Disease |
| Interventions | ; |
There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are included among the most common central nervous system tumors in childhood. The gene(s) involved in the pathogenesis of these tumors are largely not known; their possible association with other developmental defects or inheritance pattern(s) has not been investigated. The pres…
NCT00060541 — Evaluation and Treatment of Neurosurgical Disorders
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Institute of Neurological Disorders and Stroke (NINDS) |
| Enrollment | 5000 |
| Study Type | OBSERVATIONAL |
| Conditions | Neurologic Disorders |
| Interventions | ; |
Objective: This protocol is designed to allow evaluation of participants neurosurgical disorders that receive care within the Surgical Neurology Branch. The participants will receive standard-of-clinical-care evaluation and treatment. The clinical data and samples generated during standard of care treatment will be collected as a part of this study.
Study Population: Participants 4 years of ag…
NCT03831958 — Long-Term Follow-Up of Survivors of Pediatric Cushing Disease
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Enrollment | 600 |
| Study Type | OBSERVATIONAL |
| Conditions | Cushing Disease |
Background:
The pituitary gland produces hormones. A tumor in this gland can cause it to produce too much of the hormone cortisol. Too much cortisol in the body causes Cushing disease. This disease causes many problems. Some of these problems might persist after the disease is cured.
Objective:
To find out the long-term effects of exposure to high levels of cortisol during childhood and adol…
NCT03867448 — Study of Endocrine-Related Conditions and Physiology
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Enrollment | 1000 |
| Study Type | OBSERVATIONAL |
| Conditions | Endocrine Disease |
| Interventions |
Background:
Endocrine disorders involve changes to glands that produce hormones. Hormones are released by these glands into the blood so they can direct the function of other tissues in the body. Researchers want to study people who may have endocrine disorders. They want to learn more about the conditions that affect endocrine glands.
Objective:
To study adults with a variety of endocrine d…
NCT05237440 — Childhood Traumas in Obese Women: Association With Deregulation of the Glucocorticoid Axis and Inflammatory State.
| Status | Recruiting |
| Phase | N/A |
| Sponsor | University Hospital, Limoges |
| Enrollment | 102 |
| Study Type | INTERVENTIONAL |
| Conditions | Obesity |
| Interventions |
We postulate that childhood traumas are associated with deregulation of the glucocorticoid axis and the inflammatory system in obese women. The main objective of the study is to compare the salivary cortisol awaking response in obese women according to the presence of childhood trauma (assessed using the Childhood Trauma Questionnaire, CTQ).
NCT05804669 — A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing’s Syndrome
| Status | Recruiting |
| Phase | Phase 1 / Phase 2 |
| Sponsor | Crinetics Pharmaceuticals Inc. |
| Enrollment | 18 |
| Study Type | INTERVENTIONAL |
| Conditions | Cushing Syndrome; Cushing Disease; Ectopic ACTH Syndrome |
| Interventions |
A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adrenocorticotropic hormone [ACTH] receptor antagonist) in participants with ACTH-dependent Cushing’s syndrome (Cushing’s disease or Ectopic ACTH Syndrome [EAS])
NCT06471829 — A Trial of Lu AG13909 in Adult Participants With Cushing’s Disease
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | H. Lundbeck A/S |
| Enrollment | 18 |
| Study Type | INTERVENTIONAL |
| Conditions | Cushing’s Disease |
| Interventions |
This trial will evaluate the effects of Lu AG13909 in adult participants with Cushing’s disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol. The main goals of this trial are to learn about
- the effect of Lu AG13909 on cortisol levels.
- the safety and tolerability of Lu AG13909.
- the pharmacokinetic parameters of Lu AG13909 (how the d…
NCT05958342 — CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Jason Sperry |
| Enrollment | 1050 |
| Study Type | INTERVENTIONAL |
| Conditions | Trauma; Hemorrhage |
| Interventions | ; ; |
The CAlcium and VAsopressin following Injury Early Resuscitation (CAVALIER) Trial is a proposed 4 year, double-blind, mutli-center, prehospital and early in hospital phase randomized trial designed to determine the efficacy and safety of prehospital calcium and early in hospital vasopressin in patients at risk of hemorrhagic shock.
NCT04867317 — Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | VA Office of Research and Development |
| Enrollment | 172 |
| Study Type | INTERVENTIONAL |
| Conditions | Adult Growth Hormone Deficiency; Mild Traumatic Brain Injury |
| Interventions | ; |
The purpose of this study is to determine whether growth hormone replacement therapy (GHRT) is effective versus placebo in the improvement of Quality of Life in patients with adult growth hormone deficiency (AGHD) and mild traumatic brain injury (mTBI).
NCT06587035 — A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India.
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Pfizer |
| Enrollment | 50 |
| Study Type | OBSERVATIONAL |
| Conditions | Dwarfism, Pituitary |
| Interventions |
The purpose of this study is to learn about the safety of Somatrogon for the treatment of pediatric growth hormone deficiency (p GHD) in India.
Pediatric GHD is a condition caused by too less amounts of growth hormone in the body. Children with GHD have a short height. GHD can be present at birth or develop later. The condition occurs if the pituitary gland makes too little growth hormone. Thi…
NCT06930625 — A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Debiopharm International SA |
| Enrollment | 119 |
| Study Type | INTERVENTIONAL |
| Conditions | Acromegaly |
| Interventions | ; |
The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison to placebo at week 36.
NCT07221851 — Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Ascendis Pharma A/S |
| Enrollment | 186 |
| Study Type | INTERVENTIONAL |
| Conditions | Turner Syndrome; Short Stature Homeobox Gene Mutation; Idiopathic Short Stature; Small for Gestational Age at Delivery |
| Interventions | ; |
This basket trial will enroll prepubertal children and adolescents with clinically diagnosed and genetically confirmed (if applicable) TS, SHOX-D, SGA, or ISS between ages of ≥2 and <18 years with open growth plates. The purpose of the study is to see how well treatment with once-weekly lonapegsomatropin works compared to treatment with daily somatropin. Approximately 186 participants will be …
NCT07316101 — Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery
| Status | Recruiting |
| Phase | N/A |
| Sponsor | West China Hospital |
| Enrollment | 20 |
| Study Type | INTERVENTIONAL |
| Conditions | Pituitary Adenoma; Craniopharyngioma |
| Interventions |
The goal of this clinical trial is to learn if the anti-fog suction device works to keep the surgical view clear during endoscopic nose-to-pituitary operations and whether it lowers the chance of brain-fluid infection. It will also learn about the safety of the device.
The main questions it aims to answer are:
- Does the device reduce the total time the surgeon has to stop because the lens fo…
NCT07235917 — A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Regeneron Pharmaceuticals |
| Enrollment | 34 |
| Study Type | INTERVENTIONAL |
| Conditions | Functional Hypothalamic Amenorrhea (FHA) |
| Interventions | ; |
This study is researching an experimental drug called mibavademab (also called “study drug”). The study is focused on patients with a condition called Functional Hypothalamic Amenorrhea (FHA). FHA is a condition where a woman stops menstruating because the brain is not sending the correct hormonal signals to the ovaries, which then are not able to cycle and ovulate properly.
The aim of the stu…
NCT07460232 — FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease
| Status | Recruiting |
| Phase | Early Phase 1 |
| Sponsor | Mayo Clinic |
| Enrollment | 50 |
| Study Type | INTERVENTIONAL |
| Conditions | Cushing Disease; Pituitary Adenoma |
| Interventions |
The purpose of this research is to evaluate the performance [sensitivity, specificity, accuracy] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.
NCT06948214 — Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Lumos Pharma |
| Enrollment | 150 |
| Study Type | INTERVENTIONAL |
| Conditions | Growth Hormone Deficiency (GHD) |
| Interventions | ; |
The OraGrowtH Phase 3 Trial is a multi-national trial. The goals of the trial are to study LUM-201 as a treatment for Pediatric Growth Hormone Deficiency (PGHD) in naive to treatment children and validate the LUM-201 predictive enrichment marker (LUM-201 PEM) strategy to select subjects likely to respond to therapy with daily oral LUM-201.
NCT07583563 — An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Camurus AB |
| Enrollment | 200 |
| Study Type | OBSERVATIONAL |
| Conditions | Acromegaly |
| Interventions |
The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.
NCT07553351 — GB06 Phase III Trial for Pediatric Growth Hormone Deficiency
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Kexing Biopharm Co., Ltd. |
| Enrollment | 192 |
| Study Type | INTERVENTIONAL |
| Conditions | Growth Hormone Deficiency (GHD); Growth Hormone Deficiency in Children; Growth Hormone Deficiency, Pediatric |
| Interventions | ; |
This study aims to evaluate the efficacy and safety of GB06 (a biosimilar of Norditropin®FlexProTM from Novo Nordisk) for the treatment of growth disorders caused by growth hormone deficiency (GHD) in children.
It aims to determine whether the annual height velocity (an index of height growth rate) in children diagnosed with GHD after 52 weeks of GB06 intervention is comparable to that of Nord…
NCT07569861 — Copeptin Measurement After Mannitol and Hypertonic Saline for the Diagnosis of Polyuria-polydipsia Syndrome
| Status | Recruiting |
| Phase | N/A |
| Sponsor | University Hospital, Basel, Switzerland |
| Enrollment | 144 |
| Study Type | INTERVENTIONAL |
| Conditions | Arginine Vasopressin Deficiency; Primary Polydipsia |
| Interventions | ; |
The aim of this study is to evaluate whether a new test using mannitol infusion can diagnose the cause of polyuria-polydipsia syndrome as accurately as the current standard test (hypertonic saline infusion) and to compare which test patients prefer. The goal is to identify a simpler and more patient-friendly diagnostic approach.
NCT07493447 — Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
| Status | Recruiting |
| Phase | Early Phase 1 |
| Sponsor | Eben Rosenthal |
| Enrollment | 30 |
| Study Type | INTERVENTIONAL |
| Conditions | Meningioma; Glioblastoma; Acoustic Neuroma; Brain Cancer; Pituitary Adenoma |
| Interventions |
This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.
NCT07464860 — Feasibility of Breathwork Intervention With Older Adults After Knee Surgery
| Status | Recruiting |
| Phase | N/A |
| Sponsor | University of Arizona |
| Enrollment | 32 |
| Study Type | INTERVENTIONAL |
| Conditions | Surgical Stress Response; Stress Physiological; Stress Physiology; Stress Psychological; Breathing Techniques |
| Interventions | ; |
Postoperative complications after surgical procedures, including following total knee arthroplasty (TKA), have a negative impact on the health and well-being of surgical patients. Older adults (≥65 years) are particularly vulnerable to postoperative complications and their associated morbidities due to the biological aging process. Older adults comprise nearly half of surgical patients worldwid…
Active, Not Recruiting
NCT00209235 — Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
| Status | Active, not recruiting |
| Phase | N/A |
| Sponsor | Connecticut Children’s Medical Center |
| Enrollment | 600 |
| Study Type | INTERVENTIONAL |
| Conditions | Pseudohypoparathyroidism Type 1A; Albright Hereditary Osteodystrophy; Pseudopseudohypoparathyroidism |
| Interventions |
We, the researchers, are following the natural history of Albright hereditary osteodystrophy. We have found that growth hormone deficiency is very common in patients with pseudohypoparathyroidism type 1A, which falls under the broader condition termed Albright hereditary osteodystrophy. Patients with pseudohypoparathyroidism type 1A typically are short and obese. Some of these patients are not …
NCT02834013 — Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Sponsor | National Cancer Institute (NCI) |
| Enrollment | 798 |
| Study Type | INTERVENTIONAL |
| Conditions | Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortical Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma |
| Interventions | ; ; |
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
This trial enrolls participants for the following cohorts based on condition:
- Epithelial tumors of na…
NCT03655223 — Early Check: Expanded Screening in Newborns
| Status | Active, not recruiting |
| Phase | N/A |
| Sponsor | RTI International |
| Enrollment | 30000 |
| Study Type | OBSERVATIONAL |
| Conditions | Spinal Muscular Atrophy; Fragile X Syndrome; Fragile X - Premutation; Duchenne Muscular Dystrophy; Hyperinsulinemic Hypoglycemia, Familial 1 |
| Interventions |
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and families who screen positive, and 3) evaluate the Early Check program. The Early Check screening will lead to earlier identification of newborns with rare health condi…
NCT04261712 — A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Sponsor | Crinetics Pharmaceuticals Inc. |
| Enrollment | 43 |
| Study Type | INTERVENTIONAL |
| Conditions | Acromegaly |
| Interventions |
A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.
NCT04790175 — Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH
| Status | Active, not recruiting |
| Phase | N/A |
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Enrollment | 300 |
| Study Type | OBSERVATIONAL |
| Conditions | Antidiuretic Hormone, Inappropriate Secretion |
| Interventions |
The purpose of this study is to confirm the safety of tolvaptan in patients with hyponatremia in syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Japan
Not Yet Recruiting
NCT07618949 — Standardized Patient Education in Pituitary Surgery
| Status | Not yet recruiting |
| Phase | N/A |
| Sponsor | Uludag University |
| Enrollment | 102 |
| Study Type | INTERVENTIONAL |
| Conditions | Pituitary Adenoma |
| Interventions |
Protocols are being developed and implemented to ensure the best possible recovery process for patients undergoing transsphenoidal surgery, and their impact on patient outcomes is being evaluated. In studies where perioperative protocols-including patient education (verbal and written instruction on dehydration, hyponatremia, adrenal insufficiency, CSF leakage, meningitis, and the signs and sym…
NCT07663318 — A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)
| Status | Not yet recruiting |
| Phase | Phase 1 |
| Sponsor | Triastek (Shanghai) Limited |
| Enrollment | 18 |
| Study Type | INTERVENTIONAL |
| Conditions | Acromegaly |
| Interventions | ; ; |
The goal of this clinical trial] is to to Assess the Food Effect on the Relative Bioavailability of Orally Administrated T25 in healthy volunteers. The main questions it aims to answer are:
- How much of relative bioavailability of Orally Administrated T25 compared to Mycapssa?
- What effects does of food have on the pharmacokinetic profile of T25 when administerted under high fat diet?
Pa…
NCT07641179 — A Study to Evaluate MAR002 for Acromegaly
| Status | Not yet recruiting |
| Phase | Phase 2 |
| Sponsor | Marea Therapeutics |
| Enrollment | 72 |
| Study Type | INTERVENTIONAL |
| Conditions | Acromegaly |
| Interventions | ; |
Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly
NCT07659912 — Direct Versus Video Laryngoscopy in Patients With Acromegaly
| Status | Not yet recruiting |
| Phase | N/A |
| Sponsor | Muzaffer GENCER |
| Enrollment | 40 |
| Study Type | OBSERVATIONAL |
| Conditions | Acromegaly; Nonfunctioning Pituitary Adenoma |
Acromegaly is associated with craniofacial skeletal changes and upper airway soft tissue hypertrophy, which may increase the risk of difficult laryngoscopy and tracheal intubation. This prospective observational study aims to evaluate airway and intubation characteristics in patients with acromegaly undergoing surgery under general anesthesia and to compare direct laryngoscopy and video laryngo…
NCT07129759 — Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency
| Status | Not yet recruiting |
| Phase | Phase 3 |
| Sponsor | Lumos Pharma |
| Enrollment | 150 |
| Study Type | INTERVENTIONAL |
| Conditions | Growth Hormone Deficiency (GHD) |
| Interventions |
This is a Multi-national Trial. The Goal of the Trial is to Offer Subjects Who Complete 12 Months in the LUM-201-10 Phase 3 Trial up to an Additional 36 Months of Treatment of LUM-201 While Evaluating Safety and Tolerability of LUM-201.
Enrolling by Invitation
NCT05718570 — A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information
| Status | Enrolling by invitation |
| Phase | N/A |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 400 |
| Study Type | OBSERVATIONAL |
| Conditions | Adult Growth Hormone Deficiency |
| Interventions |
In this study, the general long-term safety and effectiveness of Sogroya (somapacitan) in adults with growth hormone deficiency (AGHD) being treated per normal clinical practice is looked into. In the study, information on side effects and how well Sogroya (somapacitan) works during long term treatment in people with Adult Growth Hormone Deficiency (AGHD) will be collected and analysed. Partici…
NCT07108244 — Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing’s Disease
| Status | Enrolling by invitation |
| Phase | N/A |
| Sponsor | University Hospital, Basel, Switzerland |
| Enrollment | 43 |
| Study Type | INTERVENTIONAL |
| Conditions | Cushing Disease |
| Interventions |
In ACTH-dependent hypercortisolism it is important to distinguish between Cushing’s disease (CD), with ACTH production by a pituitary neuroendocrine tumour (PitNET) and Cushing’s syndrome (CS), with ectopic ACTH production. Bilateral inferior petrosal sinus sampling (IPSS) is the gold standard for this distinction, with a diagnostic accuracy of 98%. However, IPSS is an invasive procedure and an…
Completed Trials
NCT00001452 — Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex
| Status | Completed |
| Phase | N/A |
| Sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Enrollment | 1387 |
| Study Type | OBSERVATIONAL |
| Conditions | Cushing’s Syndrome; Pituitary Adenoma; Carney Complex; Primary Pigmented Nodular Adrenocortical Disease; Peutz-Jeghers Syndrome |
| Interventions |
Lentiginosis refers to groups of diseases marked by the presence of pigmented spots on the skin. These conditions are most commonly associated with multiple tumors and changes in hormone producing glands. The cause of these diseases is unknown, but researchers suggest there may be a level of inheritance involved in their development. Meaning to say that some of these diseases may “run in the fa…
NCT00073801 — Pelvic Pain in Women With Endometriosis
| Status | Completed |
| Phase | N/A |
| Sponsor | National Institute of Neurological Disorders and Stroke (NINDS) |
| Enrollment | 78 |
| Study Type | OBSERVATIONAL |
| Conditions | Endometriosis; Chronic Pelvic Pain |
This study will examine pelvic pain associated with endometriosis and explore better approaches to treatment. In women with endometriosis, uterine tissue grows outside the uterus. Standard treatments - altering hormone levels to prevent endometrial tissue growth or surgically removing endometrial tissue - treat pelvic pain only temporarily. This study will investigate the role of sex hormones, …
NCT01247675 — A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Ascendis Pharma A/S |
| Enrollment | 37 |
| Study Type | INTERVENTIONAL |
| Conditions | Adult Growth Hormone Deficiency |
| Interventions | ; ; |
This study investigates the safety, tolerability, pharmacokinetic profile (PK), and pharmacodynamic response (PD) of three different doses of ACP-001 given once-a-week compared to one dose-level of an approved daily human growth hormone product over a period of 4 weeks (4 weekly administrations versus 28 daily administrations) in adults with Growth Hormone Deficiency.
NCT02377583 — Hypothalamo-pituitary Adrenal Axis Activity and Neuropsychological Consequences in Type 1 Diabetes in Childhood
| Status | Completed |
| Phase | N/A |
| Sponsor | University Hospital, Bordeaux |
| Enrollment | 79 |
| Study Type | INTERVENTIONAL |
| Conditions | Type 1 Diabetes |
| Interventions |
The general objective is to precise the role of HPA axis activity in neuropsychological consequences of type 1 diabetes. The investigators hypothesize that hyperactivity of HPA axis is associated with higher scores of depression and changes in hippocampal volume and mean diffusion.
NCT01947907 — Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Ascendis Pharma A/S |
| Enrollment | 53 |
| Study Type | INTERVENTIONAL |
| Conditions | Growth Hormone Deficiency (GHD) |
| Interventions | ; |
A six month study of ACP-001, a long-acting growth hormone product, versus standard human growth hormone therapy. ACP-001 will be given once-a-week, standard human growth hormone (hGH) will be given on a daily basis. The primary aim is to demonstrate safety, pharmacokinetics and pharmacodynamics over a period of six months. A secondary objective is the comparison of height velocity (HV) of the …
NCT02781727 — A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | Ascendis Pharma Endocrinology Division A/S |
| Enrollment | 162 |
| Study Type | INTERVENTIONAL |
| Conditions | Growth Hormone Deficiency, Pediatric; hGH (Human Growth Hormone); Endocrine System Diseases; Hormones; Pituitary Diseases |
| Interventions | ; |
A 52 week trial of TransCon hGH, a long-acting growth hormone product, versus human growth hormone therapy. TransCon hGH will be given once-a-week, human growth hormone (hGH) will be given daily. Approximately 150 prepubertal, hGH-treatment naïve children (males and females) with GHD will be included. Randomization will occur in a 2:1 ratio (TransCon hGH : Genotropin). This is a global trial th…
NCT03305016 — A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | Ascendis Pharma Endocrinology Division A/S |
| Enrollment | 146 |
| Study Type | INTERVENTIONAL |
| Conditions | Growth Hormone Deficiency, Pediatric; Endocrine System Diseases; Hormone Deficiency; Pituitary Diseases |
| Interventions |
A 26 week trial of TransCon hGH, a long-acting growth hormone product, administered once-a-week. Approximately 150 children (males and females) with growth hormone deficiency (GHD) will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, the United States, Canada, Australia, and New Zealand.
NCT03344458 — A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | Ascendis Pharma A/S |
| Enrollment | 298 |
| Study Type | INTERVENTIONAL |
| Conditions | Growth Hormone Deficiency, Pediatric; Endocrine System Diseases; Hormone Deficiency; Pituitary Diseases |
| Interventions |
A multicenter, phase 3, long-term extension trial of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who previously participated in a phase 3 TransCon hGH trial. Approximately 300 children (males and females) with GHD will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, th…
NCT07629713 — The Effect of Local Anesthesia on Postopanalgesia in Patients Using Head Holder
| Status | Completed |
| Phase | Phase 4 |
| Sponsor | Kocaeli University |
| Enrollment | 75 |
| Study Type | INTERVENTIONAL |
| Conditions | Postoperative Pain, Acute |
| Interventions | ; |
Aim:The head holder used in neurosurgery operations causes pain in patients both peroperatively and postoperatively.Severe pain-related hemodynamic changes are seen in these participants.In our study, the investigators compared the effects of two different concentrations of lidocaine on the perioperative and postoperative hemodynamic response caused by the application of the head-holder, and th…
NCT04042753 — Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Enrollment | 10 |
| Study Type | INTERVENTIONAL |
| Conditions | Pituitary; Pituitary Tumor; Pituitary Carcinoma; Pituitary Cancer |
| Interventions | ; ; |
The purpose of this study is to determine if nivolumab and ipilimumab are effective treatment for people with pituitary tumors have gotten worse after surgery and radiation.
NCT04349839 — ACRODAT Prospective Evaluation Study
| Status | Completed |
| Phase | N/A |
| Sponsor | University of Aarhus |
| Enrollment | 500 |
| Study Type | OBSERVATIONAL |
| Conditions | Acromegaly |
| Interventions |
ACRODAT® is a new software medical device developed by a group of acromegaly experts to help practising endocrinologists assess disease activity in patients with acromegaly. It uses 5 key parameters (IGF-I level, tumour status, comorbidities, symptoms and Quality of life) to evaluate the patient’s health status. The purpose of this post marketing surveillance study is to prospectively evaluate …
NCT04615273 — A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | Ascendis Pharma Endocrinology Division A/S |
| Enrollment | 264 |
| Study Type | INTERVENTIONAL |
| Conditions | Growth Hormone Deficiency; Endocrine System Diseases; Hormone Deficiency |
| Interventions | ; ; |
A 38-week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control. A daily somatropin product arm is also included to assist clinical judgement on the trial results. A total of 264 adults (males and females) with growth hormone deficiency were included. Randomization occurred in a 1:1:1 ratio (lonapegsomatropin: placebo: daily som…
NCT04614337 — Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Lumos Pharma |
| Enrollment | 104 |
| Study Type | INTERVENTIONAL |
| Conditions | Growth Hormone Deficiency |
| Interventions | ; |
This is a multi-national trial. The goals of the trial are to study LUM-201 as a possible treatment for Pediatric Growth Hormone Deficiency (PGHD) and investigate a predictive enrichment marker (PEM) strategy to select subjects likely to respond to therapy with LUM-201.
NCT05171855 — A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | Ascendis Pharma Endocrinology Division A/S |
| Enrollment | 220 |
| Study Type | INTERVENTIONAL |
| Conditions | Adult Growth Hormone Deficiency; Endocrine System Diseases; Hormone Deficiency |
| Interventions |
This was a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly. The study participants were adults (males and females) with confirmed growth hormone deficiency (GHD) having completed the treatment period in study TCH-306 (foresiGHt; NCT04615273).
NCT06659692 — Pharmacokinetics of FSH and hCG Following Multiple Dose of Gonadotropins-IBSA.
| Status | Completed |
| Phase | Phase 1 |
| Sponsor | IBSA Institut Biochimique SA |
| Enrollment | 28 |
| Study Type | INTERVENTIONAL |
| Conditions | Ovarian Stimulation; Infertility |
| Interventions |
Pharmacokinetics of FSH and hCG after multiple subcutaneous injection of Gonadotropins-IBSA.
Other (Withdrawn)
NCT03297892 — Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015
| Status | Withdrawn |
| Phase | N/A |
| Sponsor | University Hospital, Brest |
| Enrollment | N/A |
| Study Type | OBSERVATIONAL |
| Conditions | Cushing Disease |
Cushing’s disease is a rare disease that can reduce patients’ expectations or quality of life, and for which predictive factors for cardiovascular mortality and recurrence are not well defined.
The primary objective is to determine the rates of remission and recurrence of patients with Cushing’s disease diagnosed between 1990 and 2015 in the French region of the West (Angers, Brest, Nantes, Re…